thalidomide has been researched along with Liposarcoma in 1 studies
Thalidomide: A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppressive and anti-angiogenic activity. It inhibits release of TUMOR NECROSIS FACTOR-ALPHA from monocytes, and modulates other cytokine action.
thalidomide : A racemate comprising equimolar amounts of R- and S-thalidomide.
2-(2,6-dioxopiperidin-3-yl)-1H-isoindole-1,3(2H)-dione : A dicarboximide that is isoindole-1,3(2H)-dione in which the hydrogen attached to the nitrogen is substituted by a 2,6-dioxopiperidin-3-yl group.
Liposarcoma: A malignant tumor derived from primitive or embryonal lipoblastic cells. It may be composed of well-differentiated fat cells or may be dedifferentiated: myxoid (LIPOSARCOMA, MYXOID), round-celled, or pleomorphic, usually in association with a rich network of capillaries. Recurrences are common and dedifferentiated liposarcomas metastasize to the lungs or serosal surfaces. (From Dorland, 27th ed; Stedman, 25th ed)
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, Y | 1 |
| Xu, L | 1 |
| Mayakonda, A | 1 |
| Huang, ML | 1 |
| Kanojia, D | 1 |
| Tan, TZ | 1 |
| Dakle, P | 1 |
| Lin, RY | 1 |
| Ke, XY | 1 |
| Said, JW | 1 |
| Chen, J | 1 |
| Gery, S | 1 |
| Ding, LW | 1 |
| Jiang, YY | 1 |
| Pang, A | 1 |
| Puhaindran, ME | 1 |
| Goh, BC | 1 |
| Koeffler, HP | 1 |
1 other study available for thalidomide and Liposarcoma
| Article | Year |
|---|---|
Bromodomain and extraterminal proteins foster the core transcriptional regulatory programs and confer vulnerability in liposarcoma.
Topics: Animals; Azepines; Base Sequence; Carcinogenesis; Cell Line, Tumor; Enhancer Elements, Genetic; Geno | 2019 |